![]() This guidance excludes revenue from the anticipated AYVAKIT indication expansion in indolent systemic mastocytosis (ISM) in mid-2023. Anticipate $130 million to $140 million in AYVAKIT net product revenues in 2023 for advanced systemic mastocytosis (SM) and GIST.Recorded global AYVAKIT®/AYVAKYT® (avapritinib) net product revenues of $111.0 million and $30.1 million for the full year and the fourth quarter of 2022, respectively, representing more than 100 percent year-over-year growth."In 2023, Blueprint Medicines has a diversity of fundamental value drivers that position us well on the path to achieve our 2027 Blueprint for Precision at Scale and translate the promise of precision medicine into reality for thousands of patients globally."įourth Quarter 2022 Highlights and Recent Progress ![]() In addition to our commercial execution, we advanced additional clinical development programs and continued to bolster our financial strength through our strategic financing and business development," said Kate Haviland, Chief Executive Officer of Blueprint Medicines. Today, we are at the precipice of a pivotal moment in Blueprint's history as we near a potential FDA approval of AYVAKIT for a much broader population of patients with indolent SM, which will enable us to address the significant medical needs of SM patients and create a critical inflection point in our growing revenue stream. ![]() It's best to go with the majority and send as many replies as possible without worrying about the quality of what's being sent, since it doesn't matter when nobody is paying - more."In 2022, AYVAKIT became the standard of care for patients with advanced systemic mastocytosis in the U.S., and we continued to solidify our global leadership in mast cell disorders. We're just told to keep numbers up instead of recognition for knowing our roles. Solving problems goes completely unnoticed while someone is spamming out nonsense to customers to keep their numbers up where it may take someone else 15 minutes to craft the one reply that is the solution. Now it's calculated based on the average replies per hour. Years ago the quality of work was the most important aspect of this job. One of the engagements is a support ticketing system. The pay is okay and that is the only positive attribute about this company. There's a point system for attendance with long lines for the clock out machine. No phones allowed also applies to parents - no exceptions. ![]() Since no phones are allowed at desks, a missed shuttle in the morning means nobody can really help. For those with daycare schedules, college classes, etc - there is no flexibility with scheduling.Ī few buildings do not have enough parking passes, there's a shuttle bus to take people to their cars which adds an extra 20-30 minutes to commute time. PTO blackout dates during holidays, mandatory overtime, and a schedule is provided without consideration of outside conflicts. This is a distraction from the zero work/life balance. The company culture is insufferable and almost cult-like complete with weekly emails to remind everyone how awesome they are. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |